Planned safety analysis of a breast cancer prevention study reveals encouraging news for Exemestane

December 14, 2008

An interim analysis of a breast cancer prevention study using exemestane (Aromasin®) finds an "acceptable" level of bone loss.

The ongoing phase II study details reported today, by Jennifer Eng-Wong, MD, a breast cancer specialist at Georgetown's Lombardi Comprehensive Cancer Center at the San Antonio Breast Cancer Symposium, examines the use of exemestane in postmenopausal women who are at an increased risk of developing breast cancer based on commonly used risk assessment measures. In addition to exemestane, all the study participants received calcium carbonate and vitamin D.

Wong's report represents findings from a planned interim safety analysis in 18 women who completed one year of exemestane.

"We found a drop in bone mineral density in these women similar to what we've seen in women taking exemestane in the adjuvant treatment setting." Eng-Wong reports. "Like aromatase inhibitors in the adjuvant setting there is a small amount of bone loss in the spine and hip. The long term clinical impact of the small decrease is not known."

The exemestane study continues with endpoints including bone density measurements and change in breast density over two years of treatment. Dense breasts as observed on a mammogram are associated with an increase in a woman's risk of developing breast cancer.

Source: Georgetown University

Explore further: Exemestane may be another first-line, adjuvant therapy for hormone-receptor positive, early-stage breast cancer

Related Stories

Hormone-blocking drug reduces breast cancer risk

June 4, 2011

(AP) -- Millions of women at higher-than-usual risk of breast cancer have a new option for preventing the disease. Pfizer Inc.'s Aromasin cut the risk of developing breast cancer by more than half, without the side effects ...

The future of breast cancer prevention

March 31, 2011

Drugs could be used to prevent breast cancer in women at high risk of the disease in the same way that statins are used for heart disease if trials looking at ways of predicting risk are successful, according to an international ...

Recommended for you

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

(PhysOrg.com) -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...

Quantum Theory May Explain Wishful Thinking

April 14, 2009

(PhysOrg.com) -- Humans don’t always make the most rational decisions. As studies have shown, even when logic and reasoning point in one direction, sometimes we chose the opposite route, motivated by personal bias or simply ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

E_L_Earnhardt
1 / 5 (1) Dec 14, 2008
CYROABLATION WORKS, and it has no side effects!

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.